Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoMix 30 Titrate-to-target in T2DM
NCT01486862Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2005
- Primary completion
- Jul 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of biphasic insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Percentage of subjects achieving HbA1c below 7.0%. Started Oct 2005; status: completed.
02
Drugs
biphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01486862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01486862.